| Name | Title | Contact Details |
|---|
American Specialty Health Incorporated (ASH) provides health plans, employer groups, insurance carriers and trust funds with a wide range of wellness and population health, fitness and exercise, and specialty health care management programs to improve the health of their employees or members. Our Healthyroads® program is one of the largest employee wellness and prevention programs, serving hundreds of employer groups and more than 5 million members across the country. From telephone and online health coaching to wellness incentive programs to worksite health challenges, we offer it all under one roof. Our fitness and exercise services, including Silver&Fit® for Medicare Advantage members and Active&Fit® for commercial members, provide no-cost, low-cost, discount, or reimbursement fitness club/exercise center membership programs; walking, home exercise, and reward programs; as well as Internet-based exercise tools. And our specialty health provider programs for health plans contract with more than 30,000 specialty health care practitioners. Headquartered in Carmel, IN, with offices in San Diego, CA, Dallas, TX and Columbia, S.C., ASH has more than 1,200 employees and administers programs for more than 31 million members nationwide. Other products offered through ASH and its subsidiaries include ExerciseRewards™, FitnessCoach™, and others.
Capital Senior Living Corporation is one of the nation`s largest operators of residential communities for senior adults. With a goal of offering affordable housing and an enriched lifestyle to thousands of seniors, our dedicated team of professionals succeeds in providing quality care in each of our unique communities.
Foot Levelers, Inc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Foot Levelers, Inc is based in Roanoke, VA. You can find more information on Foot Levelers, Inc at www.footlevelers.com
Brownsboro Park Retirement Community is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic